COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Coversin (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms COBALT
- Sponsors Akari Therapeutics
- 06 Feb 2018 According to an Akari Therapeutics media release, the final three patients enrolled in COBALT clinical trial with PNH who have never received a complement blocking therapy and now have completed the trial.
- 06 Feb 2018 Status changed from recruiting to completed, according to an Akari Therapeutics media release.
- 08 Dec 2017 Results published in the Akari Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial History